The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...